Safety and immunogenicity of the third and fourth doses of vaccine against SARS-CoV-2 following a 2-dose regimen of inactivated whole-virion SARS-CoV-2 vaccine.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 11 2023
13 11 2023
Historique:
received:
24
05
2023
accepted:
23
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
13
11
2023
Statut:
epublish
Résumé
This study followed healthcare personnel (HCP) who had completed a primary series of CoronaVac and then received the third and fourth doses of COVID-19 vaccine. The primary objective was to determine the seroconversion rate of neutralizing antibodies against wild-type SARS-CoV-2 and VOCs at day 28 after the third dose of vaccine and day 28 after the fourth dose of vaccine. This prospective cohort study was conducted at Maharaj Nakorn Chiang Mai Hospital, a tertiary care hospital affiliated to Chiang Mai University from July 2021 to February 2022. Two hundred and eighty-three participants were assessed for eligibility; 142 had received AZD1222 and 141 BNT162b2 as the third dose. Seroconversion rates using a 30% inhibition cutoff value against wild-type SARS-CoV-2 were 57.2%, 98.6%, 97.8%, and 98.9% at points before and after the third dose, before and after the fourth dose, respectively among those receiving AZD1222 as the third dose. Frequencies were 31.9%, 99.3%, 98.9%, and 100% among those receiving BNT162b2 as the third dose, respectively. The seroconversion rates against B.1.1.529 [Omicron] were 76.1% and 90.2% (p-value 0.010) at 4 weeks after the third dose in those receiving AZD1222 and BNT162b2 as the third dose, respectively. After a booster with the mRNA vaccine, the seroconversion rates increased from 21.7 to 91.3% and from 30.4 to 91.3% in those receiving AZD1222 and BNT162b2 as the third dose, respectively. No serious safety concerns were found in this study. In conclusion, antibody responses waned over time regardless of the vaccine regimen. The booster dose of the vaccine elicited a humoral immune response against SARS-CoV-2 including SARS-CoV-2 variants of concern, including B.1.1.529 [Omicron], which was circulating during the study period. However, the results might not be extrapolated to other Omicron sublineages.
Identifiants
pubmed: 37957189
doi: 10.1038/s41598-023-45735-7
pii: 10.1038/s41598-023-45735-7
pmc: PMC10643552
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
BNT162 Vaccine
0
ChAdOx1 nCoV-19
B5S3K2V0G8
COVID-19 Vaccines
0
sinovac COVID-19 vaccine
0
Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
19736Informations de copyright
© 2023. The Author(s).
Références
J Travel Med. 2022 May 31;29(3):
pubmed: 34918097
N Engl J Med. 2023 May 4;388(18):1726
pubmed: 37133606
EClinicalMedicine. 2022 Sep 28;54:101680
pubmed: 36188435
Hum Vaccin Immunother. 2022 Dec 31;18(1):2029111
pubmed: 35209809
Nat Rev Immunol. 2021 Aug;21(8):475-484
pubmed: 34211186
Angew Chem Int Ed Engl. 2020 Oct 19;59(43):18885-18897
pubmed: 32663348
Immunology. 2022 Oct;167(2):263-274
pubmed: 35751563
Sci Rep. 2023 Jan 2;13(1):34
pubmed: 36593231
Int Immunopharmacol. 2021 Nov;100:108095
pubmed: 34619529
Lancet. 2021 Dec 18;398(10318):2258-2276
pubmed: 34863358
Hum Vaccin Immunother. 2022 Nov 30;18(6):2091865
pubmed: 35816053
Int J Infect Dis. 2023 Apr;129:19-31
pubmed: 36682680
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Infect Dis Ther. 2023 May;12(5):1237-1264
pubmed: 37097556
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Lancet. 2022 Jan 1;399(10319):36-49
pubmed: 34883053
Nat Microbiol. 2022 Aug;7(8):1161-1179
pubmed: 35798890
Nat Commun. 2022 May 13;13(1):2670
pubmed: 35562366
Lancet. 2021 Sep 4;398(10303):856-869
pubmed: 34370971
Vaccine. 2022 Sep 16;40(39):5657-5663
pubmed: 36031500
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Nature. 2022 Mar;603(7901):493-496
pubmed: 35102312
Emerg Microbes Infect. 2022 Dec;11(1):1-5
pubmed: 34890524
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
N Engl J Med. 2023 Feb 23;388(8):764-766
pubmed: 36734847
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
Vaccines (Basel). 2023 Mar 01;11(3):
pubmed: 36992147